Coronary heart disease combined with diabetes
Conditions
Interventions
The non-naliniotone group:Patients in the finerenone group were given finerenone in addition to conventional treatment (initial dose of 10mg, once daily, and subsequently adjusted to 20mg, once daily
Control group:The control group received drug treatment based on the conventional treatment plan by the clinical physicians: lowering blood sugar (metformin tablets, dapagliflozin tablets, insulin, et
Sponsors
Pharmacy Department of Su Bei People's Hospital, Jiangsu Province
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. In accordance with the "Diagnostic Criteria for Coronary Artery Atherosclerotic Heart Disease": any major coronary artery such as the left main trunk, left anterior descending branch, left circumflex branch, right coronary artery or its main branch is narrowed by >=50%; in accordance with the "Diagnosis Criteria for Type 2 Diabetes Mellitus in China 2010 Edition": fasting plasma glucose (FPG) >= 7.0 mmol/L, 2-hour blood glucose after oral glucose tolerance test >= 11.1 mmol/L; 2. Age >= 45 years old, gender not limited; 3.Serum potassium = 25 ml/min/1.73 m^2; 5.Total follow-up time is not less than 3 months. Overall, 20 mg, once daily)
Exclusion criteria
Exclusion criteria: 1.Patients with severe liver or kidney dysfunction, myocarditis, heart valve disease, cardiomyopathy, or malignant tumors; 2. Patients with infectious diseases, thyroid disorders, or mental illnesses; 3. Patients with incomplete clinical data; 4. Patients with hyperkalemia > 5.0 mmol/L; 5. Patients allergic to the drug nonalnidin.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Left ventricular ejection fraction;Urinary albumin to creatinine ratio;Creatinine;Serum potassium;urea; | — |
Countries
China
Contacts
Public ContactLiu Jia
Pharmacy Department of Su Bei People's Hospital, Jiangsu Province
Outcome results
None listed